957 related articles for article (PubMed ID: 7586613)
21. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle.
Croxatto HB; Salvatierra AM; Croxatto HD; Fuentealba B
Hum Reprod; 1993 Feb; 8(2):201-7. PubMed ID: 8473419
[TBL] [Abstract][Full Text] [Related]
22. Shorter pill-free interval in combined oral contraceptives decreases follicular development.
Spona J; Elstein M; Feichtinger W; Sullivan H; Lüdicke F; Müller U; Düsterberg B
Contraception; 1996 Aug; 54(2):71-7. PubMed ID: 8842582
[TBL] [Abstract][Full Text] [Related]
23. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
24. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest.
Spona J; Feichtinger W; Kindermann C; Moore C; Mellinger U; Walter F; Gräser T
Contraception; 1997 Sep; 56(3):185-91. PubMed ID: 9347211
[TBL] [Abstract][Full Text] [Related]
25. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
[TBL] [Abstract][Full Text] [Related]
26. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
[TBL] [Abstract][Full Text] [Related]
27. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
29. Effect of low daily doses of mifepristone on ovarian function and endometrial development.
Danielsson KG; Swahn ML; Westlund P; Johannisson E; Seppälä M; Bygdeman M
Hum Reprod; 1997 Jan; 12(1):124-31. PubMed ID: 9043916
[TBL] [Abstract][Full Text] [Related]
30. Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: a potential new contraceptive strategy.
Batista MC; Cartledge TP; Zellmer AW; Merino MJ; Axiotis C; Loriaux DL; Nieman LK
Am J Obstet Gynecol; 1992 Jul; 167(1):60-5. PubMed ID: 1442957
[TBL] [Abstract][Full Text] [Related]
31. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years.
Barbosa I; Coutinho E; Hirsch C; Ladipo O; Olsson SE; Ulmsten U
Fertil Steril; 1996 Apr; 65(4):724-9. PubMed ID: 8654629
[TBL] [Abstract][Full Text] [Related]
32. The mechanism of action of a new low-dosed combined oral contraceptive.
Dericks-Tan JS; Schneider K; Taubert HD
Arch Gynecol; 1980; 229(2):107-14. PubMed ID: 6768343
[TBL] [Abstract][Full Text] [Related]
33. Levels of follicle-stimulating hormone, luteinizing hormone, oestradiol-17 beta and progesterone, and follicular growth in the pseudopregnant rat.
Welschen R; Osman P; Dullaart J; de Greef WJ; Uilenbroek JT; de Jong FH
J Endocrinol; 1975 Jan; 64(1):37-47. PubMed ID: 1167896
[TBL] [Abstract][Full Text] [Related]
34. Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation.
Croxatto HB; Salvatierra AM; Romero C; Spitz IM
J Clin Endocrinol Metab; 1987 Dec; 65(6):1272-7. PubMed ID: 3119656
[TBL] [Abstract][Full Text] [Related]
35. A single dose of mifepristone (200 mg) in the immediate preovulatory phase offers contraceptive potential without cycle disruption.
Brown A; Williams A; Cameron S; Morrow S; Baird DT
Contraception; 2003 Sep; 68(3):203-9. PubMed ID: 14561541
[TBL] [Abstract][Full Text] [Related]
36. Ovulation inhibition by daily i.m. administration of a highly active LH-RH analog (d-ser(TBU)6-LH-RH-(1-9)-nonapeptide-ethylamide).
Baumann R; Kuhl H; Taubert HD; Sandow J
Contraception; 1980 Feb; 21(2):191-7. PubMed ID: 6768492
[TBL] [Abstract][Full Text] [Related]
37. Ovarian activity during regular oral contraceptive use.
Crosignani PG; Testa G; Vegetti W; Parazzini F
Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
[TBL] [Abstract][Full Text] [Related]
38. Failure of oestrogen induced luteinizing hormone surge in women treated with mifepristone (RU 486) every day for 30 days.
Baird DT; Thong KJ; Hall C; Cameron ST
Hum Reprod; 1995 Sep; 10(9):2270-6. PubMed ID: 8530650
[TBL] [Abstract][Full Text] [Related]
39. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
[TBL] [Abstract][Full Text] [Related]
40. Effect of mifepristone on folliculogenesis in women treated with recombinant FSH.
Messinis IE; Krishnan M; Kazem R; Khadilkar S; Templeton AA
Clin Endocrinol (Oxf); 1997 Mar; 46(3):309-14. PubMed ID: 9156040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]